Comparative Pharmacology
Head-to-head clinical analysis: INDO LEMMON versus INDOCIN SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDO LEMMON versus INDOCIN SR.
INDO-LEMMON vs INDOCIN SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits prostaglandin synthesis by blocking cyclooxygenase (COX-1 and COX-2) enzymes, reducing inflammation, pain, and fever.
Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing synthesis of prostaglandins, which mediate inflammation, pain, and fever. It also has a direct effect on renal blood flow and platelet aggregation.
Oral: 25-50 mg 2-3 times daily. Maximum daily dose: 200 mg.
75 mg orally once daily, extended-release capsules.
None Documented
None Documented
Terminal elimination half-life is approximately 2-4 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment.
Terminal half-life is 4.5 hours (range 2.6-11.2 hours) in young adults; prolonged in elderly (up to 16 hours) and in patients with renal or hepatic impairment.
Renal excretion of unchanged drug and metabolites accounts for approximately 60% of elimination; biliary/fecal excretion accounts for approximately 40%.
Approximately 50% renal (as unchanged drug and metabolites, primarily glucuronide conjugates), 33% biliary/fecal. Indomethacin undergoes enterohepatic recirculation.
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)